KALA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -10.55%, SMA50 -28.98%, SMA200 -91.06%). The stock’s 14-day RSI is 37.09 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.16% below its high and over 7.71% above its low. Average 10-day trading volume of 224.06 thousand shares is significantly above the 3-month average of 124.47 thousand, indicating heightened recent market interest.

KALA BIO, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.93. This means the shares are trading above this model’s fair value.

KALA BIO, Inc. (NASDAQ:KALA) closed at $1.09 USD, losing -$0.08 (-7.23%) from the previous close of $1.18. The stock is currently within 5% of its 52-week low $1.07 and $1.03 thousand. With a market capitalization of about $23.90 million, KALA BIO, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-2.36). Key stats such as the average daily volume over the past year has been around 123.17 thousand shares, trading with heavier-than-usual volume. Headquartered in Arlington, MA, KALA BIO, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Avi Minkowitz, the company employs approximately 6 people and listed since July 20, 2017. Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions.

KALA BIO, Inc. generated EPS of -$5.94 over the past year. Five-year average earnings growth is 40.66%. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at $nan. Next year's EPS is expected at $34.23. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $30.00. The high target offers 3111.01% upside. The low target suggests 2652.29% downside. The mean target is $32.67. This offers 2897.25% upside. KALA BIO, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 15, 2026, missed forecasts by -98.35%. The prior quarter beat by -605.88%. Over the last six quarters, Apple has recorded several small beats. These include -23.68% in March 31, 2025.

KALA BIO, Inc. has 7.02 million shares outstanding. The public float is 4.25 million shares, elevated short interest at 6.87% of float. This equals 348.23 thousand shares. The short ratio is 1.71 days. Institutional investors hold 0.75% of the float. Insiders own 0.01%. Shah Rajeev M. holds 7.04 million shares, RA CAPITAL MANAGEMENT, L.P. has 7.04 million shares and RA CAPITAL MANAGEMENT, LLC has 4.54 million shares.

KALA BIO, Inc. trades at a P/E ratio of -0.38, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.83 suggesting the stock is closer to book value. The P/FCF stands at -0.92, also above market averages.

Our AI price prediction model suggests that KALA BIO, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.26%, with price expected at $1.00 by July 27, 2026, within a range of $0.35 to $1.64 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by October 08, 2026, with a range of $0.00 to $22.32. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 13, 2027, within a range of $0.00 to $20.80.

KALA BIO, Inc. (NASDAQ:KALA) shares are flat 8.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows KALA BIO, Inc. trading at a premium to the broader market with a P/E of -0.38. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.68, suggesting 1705.5% upside. Our AI forecast model points to short-term weakness (-8.26% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.